Revvity, NET1152010UC, GR113808,[N-methyl-³H]-

GR113808 acts as an antagonist at the 5-HT4 receptor. This receptor belongs to a family of serotonin GPCRs that modulate the release of various neurotransmitters, and is a potential drug target for improving memory and cognition. We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. References for NET1152: Dhwanil A. Dalwadi, Seongcheol Kim, Shahnawaz M. Amdani, Zhenglan Chen, Ren-Qi Huang, John A. Schetz, Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz, In Pharmacological Research, Volume 110, 2016, Pages 10-24.